As we discussed in part I of our blog series on adaptive patient recruitment, the rare disease community is constantly striving to invest in developing new treatments. While there is a huge unmet need in this area, there are recruitment tactics that effectively provide support. Beyond the introduction of an early support program, which Jaime Cohen discussed in our previous post, there are additional strategies that can assist in higher recruitment numbers for rare disease. In part II of our series on rare disease we explore further.
With another successful DIA Annual Meeting behind us, as well as some time to reflect, we wanted to thank our industry partners and colleagues for making this year’s meeting one of the best yet. We also want to highlight some of the thought-provoking work and innovations that raised the already high bar. Here goes.
Topics: Patient Centricity
The average person spends nearly 4.4 hours of leisure time in front of screens each day. People are online, on their phones or using their tablets in increasing amounts. Given this statistic, it seems natural for there to be a shift from native advertising to content marketing. It’s best to reach consumers where they already are and to push relevant content to them directly to pique interest.
We know that social media usage is up year-over-year across all ages, but how is it being put to use for clinical research? On June 11th I had the pleasure of participating in a social media forum hosted by MassBio with PatientsLikeMe, Biogen and Boston Children’s Hospital. It was an eye opening discussion that looked at the use of social media within clinical trials from the varying perspectives of advocacy groups, IRBs and pharmaceutical companies, each with different goals in mind and facing their own set of unique challenges.
The 51st Annual DIA Meeting kicked off yesterday in Washington, DC. So far it has been a whirlwind of presenting, networking and having fun at our booth (#2026 come see us)! DIA is the perfect time to announce the latest in company news, and we have no shortage of announcements to share this year.
Are you planning attend the DIA Annual Meeting later this month in Washington, DC? For those of us working in drug research and development, it’s a great time to connect with the people and organizations working to accelerate the development of new therapies and enhance patient care.
There is a huge unmet need in the rare disease community to invest in developing treatments. According to the US advocacy group Global Genes, there are more than 7,000 distinct rare diseases affecting 350,000,000 people worldwide and only 400 approved therapies. How can we adapt traditional recruitment strategies to target the right patients? The goal is to create tailored adaptive strategies aimed at extending reach and building relationships. There are many ways in which this can be done. In this first post of a series focused on adaptive recruitment for rare disease, I will explore the introduction of an early support program.
BBK Worldwide was recently chosen by the Diabetes Patient Advocacy Coalition (DPAC) to create a new corporate identity and brand to reflect the new organizations commitment to focus lawmakers’ attention on diabetes patients and their needs.
Topics: Branding and Advertising
BBK Worldwide is excited to be leading two Innovation Theater panels at this year’s DIA event, taking place June 14-18 in Washington, DC. BBK Co-Founder Bonnie A. Brescia will lead our first discussion on Monday, June 15 from 4:15-4:45 p.m. with Claire Meunier, VP, Research Engagement with The Michael J. Fox Foundation and Christel Aprigliano, CEO of the Diabetes Collective.
Topics: Patient Centricity
In earlier posts we have explored how mHealth can increase both patient engagement and site engagement. Today’s blog comes from Jason Rightmyer, Director of Research Informatics with the Institute of Aging Research (a Harvard Medical School Affiliate) who explores how mobile health technology is attributing to physician engagement. Thanks for contributing!